Subject(s)
Humans , Female , Infant , Neurocutaneous Syndromes , Skin/injuries , Skin Abnormalities , Arachnoid Cysts , Dermatology , Skin Diseases , Inpatients , Physical ExaminationSubject(s)
Humans , Female , Infant , Neurocutaneous Syndromes , Skin/injuries , Skin Abnormalities , Arachnoid Cysts , Dermatology , Skin Diseases , Inpatients , Physical ExaminationSubject(s)
Humans , Male , Adult , Middle Aged , Lymphangitis/diagnosis , Sclerosis/diagnosis , Penile Diseases/diagnosis , Diagnosis, DifferentialABSTRACT
La doxiciclina es una tetraciclina sintética aprobada por primera vez en 1967. Además de las propiedades antibacterianas de amplio espectro que posee esta molécula, se han ido descubriendo propiedades antiinflamatorias interesantes que la han convertido en una posible opción terapéutica en múltiples enfermedades no infecciosas. En el campo de la dermatología, las tetraciclinas son probablemente el antibiótico oral más prescrito, con dosis, en general, inferiores a las indicadas para procesos infecciosos, con un perfil de eficacia y seguridad óptimo. Enfermedades relacionadas con la unidad foliculosebácea, procesos granulomatosos y proliferaciones vasculares, entre otros, pueden ser tratados con doxiciclina gracias a la inhibición de las vías moleculares relacionadas con estos procesos. Las principales características de la doxiciclina, y su amplio uso en dermatología, obligan al dermatólogo a estar familiarizado con este fármaco
Doxycycline is a synthetic tetracycline that was approved in 1967. This wide-spectrum antibiotic has been shown to also have useful anti-inflammatory properties that make it suitable for the treatment of a number of noninfectious conditions. Tetracyclines are probably the most commonly prescribed antibiotics in dermatology, where they are usually used at doses lower than those effective against infections. They also have an excellent efficacy and safety profile. Because of doxycycline's ability to inhibit the molecular pathways associated with certain processes, this antibiotic can be used to treat hair follicle diseases, granulomatous diseases, and vascular proliferation, among other conditions. The main properties of doxycycline and its many applications in dermatology make this drug one that specialists should become familiar with
Subject(s)
Humans , Doxycycline/administration & dosage , Anti-Bacterial Agents/administration & dosage , Skin Diseases/drug therapyABSTRACT
Doxycycline is a synthetic tetracycline that was approved in 1967. This wide-spectrum antibiotic has been shown to also have useful anti-inflammatory properties that make it suitable for the treatment of a number of noninfectious conditions. Tetracyclines are probably the most commonly prescribed antibiotics in dermatology, where they are usually used at doses lower than those effective against infections. They also have an excellent efficacy and safety profile. Because of doxycycline's ability to inhibit the molecular pathways associated with certain processes, this antibiotic can be used to treat hair follicle diseases, granulomatous diseases, and vascular proliferation, among other conditions. The main properties of doxycycline and its many applications in dermatology make this drug one that specialists should become familiar with.
Subject(s)
Dermatology , Doxycycline , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Doxycycline/therapeutic use , Tetracyclines/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Necrobiotic Xanthogranuloma/diagnosis , Paraproteinemias/etiology , Monoclonal Gammopathy of Undetermined Significance/diagnosis , Prognosis , Necrobiotic Xanthogranuloma/pathology , Paraproteinemias/pathology , Necrobiotic Xanthogranuloma/complicationsABSTRACT
El uso de las inmunoglobulinas intravenosas en la medicina se remonta a hace más de 50 años, tras el uso como terapia sustitutiva en enfermedades inmunodeficientes. Sin embargo, las indicaciones de este tratamiento han evolucionado de tal manera que actualmente está dirigido a enfermedades donde el sistema inmune desempeña un papel relevante. En el campo de la dermatología se ha hecho un hueco interesante en algunas enfermedades, como la dermatomiositis, las enfermedades autoinmunes ampollares o la necrólisis epidérmica tóxica, entre otras. En los últimos años se ha prestado especial atención al uso de las inmunoglobulinas intravenosas, de hecho se han publicado recientemente nuevas guías sobre su uso, y qué consideraciones debemos tener en cuenta durante su uso en dermatología. Nuestra intención con este artículo es reflejar de una manera práctica el uso de las inmunoglobulinas intravenosas en la dermatología
Intravenous immunoglobulin (IVIG) replacement therapy has been used in immune deficiency diseases for more than 50 years. The indications for this treatment have evolved, however, and IVIG therapy is now used in various diseases in which the immune system plays a prominent role. IVIG therapy has carved out a niche in dermatology for the treatment of such conditions as dermatomyositis, autoimmune bullous diseases, and toxic epidermal necrolysis. Special attention has been paid to this therapy in recent years. New guidelines have been published and should be taken into consideration in dermatology. This review provides a practical guide to IVIG use in our specialty
Subject(s)
Humans , Immunoglobulins, Intravenous/therapeutic use , Skin Diseases/therapy , Dermatomyositis/therapy , Autoimmune Diseases/therapy , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/adverse effects , Infusions, Subcutaneous , Patient Selection , Practice Guidelines as Topic , PremedicationABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Myocutaneous Flap/surgery , Surgical Flaps/standards , Surgical Flaps/surgery , Lip Neoplasms/diagnosis , Lip Neoplasms/surgery , Lip Neoplasms/etiology , Lip Neoplasms/pathology , Lip Neoplasms/therapyABSTRACT
Intravenous immunoglobulin (IVIG) replacement therapy has been used in immune deficiency diseases for more than 50 years. The indications for this treatment have evolved, however, and IVIG therapy is now used in various diseases in which the immune system plays a prominent role. IVIG therapy has carved out a niche in dermatology for the treatment of such conditions as dermatomyositis, autoimmune bullous diseases, and toxic epidermal necrolysis. Special attention has been paid to this therapy in recent years. New guidelines have been published and should be taken into consideration in dermatology. This review provides a practical guide to IVIG use in our specialty.
Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Skin Diseases/therapy , Autoimmune Diseases/therapy , Contraindications, Drug , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/adverse effects , Infusions, Subcutaneous , Patient Selection , Practice Guidelines as Topic , PremedicationABSTRACT
BACKGROUND: Psoriasis has been related to a large number of cardiovascular risk factors such as hypertension, diabetes mellitus and arteriosclerosis. The increased carotid intima-media thickness (IMT) could be considered to be a marker of generalized arteriosclerosis. OBJECTIVE: To assess the effect of systemic and biological drugs on psoriatic patients' carotid IMT. METHODS: A prospective study was performed. We studied 53 patients with moderate and severe psoriasis from our psoriasis dermatological unit, analysing lipid and glucose metabolism and performing a carotid IMT sonography before introduction of systemic and biological drugs. After that, we performed an 8-month closely analytic and sonographic follow-up. RESULTS: The IMT of the patients with psoriasis treated with biological drugs tended to decrease, although this occurrence was not statistically significant (P = 0.086). The subgroup analysis revealed that patients treated with methotrexate (P = 0.045) and anti-IL-12/23 (P = 0.010) presented a decrease in their IMT levels. This analysis also showed a decrease in glycaemia and insulin levels in patients treated with TNF-alpha inhibitors and ustekinumab. CONCLUSIONS: Our study suggests that the carotid IMT may benefit from treatment with biological drugs, particularly anti-IL-12/23 and methotrexate in patients suffering from moderate and severe psoriasis. However, larger longitudinal studies should be performed to fully confirm these results.
Subject(s)
Carotid Intima-Media Thickness , Dermatologic Agents/pharmacology , Methotrexate/pharmacology , Psoriasis/drug therapy , Ustekinumab/pharmacology , Adult , Biological Products/therapeutic use , Blood Glucose/drug effects , Blood Glucose/metabolism , Dermatologic Agents/therapeutic use , Female , Humans , Insulin/blood , Lipoproteins, LDL/blood , Longitudinal Studies , Male , Methotrexate/therapeutic use , Middle Aged , Prospective Studies , Severity of Illness Index , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tunica Intima/drug effects , Tunica Media/drug effects , Ustekinumab/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Angiolymphoid Hyperplasia with Eosinophilia/pathology , Ear Auricle/pathology , Cryotherapy , BiopsySubject(s)
Lip Neoplasms/surgery , Lip/surgery , Plastic Surgery Procedures/methods , Surgical Flaps , Humans , Male , Middle AgedABSTRACT
No disponible
